Enfusion, Inc. (NYSE:ENFN) Given Consensus Rating of “Hold” by Brokerages

Enfusion, Inc. (NYSE:ENFN) has received a consensus rating of “Hold” from the six brokerages that are currently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $10.50.

Several equities analysts have commented on the stock. Piper Sandler lifted their target price on shares of Enfusion from $10.00 to $11.50 and gave the stock a “neutral” rating in a research report on Monday, December 23rd. William Blair restated a “market perform” rating on shares of Enfusion in a report on Monday, January 13th. Finally, Stifel Nicolaus boosted their price target on Enfusion from $11.00 to $13.00 and gave the company a “buy” rating in a report on Wednesday, December 18th.

Insider Buying and Selling

In related news, CFO Bradley Herring sold 4,134 shares of the firm’s stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $10.13, for a total value of $41,877.42. Following the transaction, the chief financial officer now owns 266,369 shares of the company’s stock, valued at approximately $2,698,317.97. This trade represents a 1.53 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Oleg Movchan sold 2,771 shares of the company’s stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $10.13, for a total value of $28,070.23. Following the completion of the sale, the chief executive officer now owns 526,702 shares of the company’s stock, valued at approximately $5,335,491.26. The trade was a 0.52 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 57,367 shares of company stock worth $591,335 in the last 90 days. Insiders own 36.44% of the company’s stock.

Hedge Funds Weigh In On Enfusion

Hedge funds have recently modified their holdings of the company. Harbor Capital Advisors Inc. raised its stake in Enfusion by 12.4% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company’s stock valued at $113,000 after purchasing an additional 1,315 shares during the period. Belvedere Trading LLC bought a new position in shares of Enfusion during the 3rd quarter valued at approximately $114,000. Paloma Partners Management Co bought a new stake in shares of Enfusion in the 3rd quarter worth about $157,000. The Manufacturers Life Insurance Company raised its holdings in shares of Enfusion by 27.7% in the second quarter. The Manufacturers Life Insurance Company now owns 19,562 shares of the company’s stock worth $167,000 after buying an additional 4,239 shares during the period. Finally, Centiva Capital LP boosted its stake in shares of Enfusion by 5.0% during the third quarter. Centiva Capital LP now owns 25,596 shares of the company’s stock valued at $243,000 after purchasing an additional 1,227 shares during the period. 81.05% of the stock is currently owned by institutional investors.

Enfusion Price Performance

Shares of Enfusion stock opened at $11.10 on Thursday. The business has a 50-day simple moving average of $10.66 and a 200 day simple moving average of $9.52. Enfusion has a one year low of $7.83 and a one year high of $11.38. The firm has a market capitalization of $1.43 billion, a price-to-earnings ratio of 277.44, a PEG ratio of 1.83 and a beta of 0.96.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.